Top

Published in:

01-05-2005 | Opinion Paper

Harnessing host immune responses to preneoplasia: promise and challenges

Author: Madhav V. Dhodapkar

Published in: Cancer Immunology, Immunotherapy | Issue 5/2005

Abstract

Preneoplastic lesions are more common than clinical cancer and define a population at increased risk for the development of malignancy. Recent studies suggest that the immune system has the capacity to recognize these lesions, and enrichment of preneoplasia-specific immune effectors can be detected in the tumor bed of some preneoplastic lesions such as monoclonal gammopathies. Here, I discuss the promise and challenges of harnessing the immune response against preneoplasia. Approaches to boost the natural host response to these lesions may have a major impact on reducing net cancer burden.

Bissell MJ, Radisky D (2001) Putting tumours in context. Nat Rev Cancer 1:46–54CrossRefPubMed

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70CrossRefPubMed

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette P, Pistone M, Stecker K, Zhang BM, Zhou YX, Varnholt H, Smith B, Gadd M, Chatfield E, Kessler J, Baer TM, Erlander MG, Sgroi DC (2003) Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 100:5974–5979CrossRefPubMed

Ramaswamy S, Ross KN, Lander ES, Golub TR (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33:49–54CrossRefPubMed

Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW (2002) Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 100:1417–1424PubMed

Kuehl WM, Bergsagel PL (2002) Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2:175–187CrossRefPubMed

Radisky DC, Bissell MJ (2004) Cancer: respect thy neighbor! Science 303:775–777

Kyle RA, Rajkumar SV (1999) Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am 13:1181–1202PubMed

Dhodapkar MV, Krasovsky J, Olson K (2002) T cells from the tumor microenvironment of patients with progressive myeloma can generate strong tumor specific cytolytic responses to autologous tumor loaded dendritic cells. Proc Natl Acad Sci U S A 99:13009–13013CrossRefPubMed

10.

Dhodapkar MV, Krasovsky J, Osman K, Geller MD (2003) Vigorous premalignancy specific effector T cell response in the bone marrow of patients with preneoplastic gammopathy. J Exp Med 198:1753–1757CrossRefPubMed

11.

Guerry DT, Alexander MA, Elder DE, Herlyn MF (1987) Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma. J Immunol 139:305–312PubMed

12.

Kao H, Marto JA, Hoffmann TK, Shabanowitz J, Finkelstein SD, Whiteside TL, Hunt DF, Finn OJ (2001) Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 194:1313–1323CrossRefPubMed

13.

Soria JC, Jang SJ, Khuri FR, Hassan K, Liu D, Hong WK, Mao L (2000) Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 60:4000–4004PubMed

14.

Finn OJ (2003) Premalignant lesions as targets for cancer vaccines. J Exp Med 198:1623–1626CrossRefPubMed

15.

Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991–998CrossRefPubMed

16.

Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFN-gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111CrossRefPubMed

17.

Prehn RT (1994) Stimulatory effects of immune reactions upon growths of untransplanted tumors. Cancer Res 54:908–914PubMed

18.

Daniel D, Meyer-Morse N, Bergsland EK, Dehne K, Coussens LM, Hanahan D (2003) Immune enhancement of skin carcinogenesis by CD4+ T cells. J Exp Med 197:1017–1028CrossRefPubMed

19.

Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860–867CrossRefPubMed

20.

Pardoll D (2003) Does the immune system see tumors as foreign or self? Annu Rev Immunol 21:807–839CrossRefPubMed

21.

Yu P, Lee Y, Liu W, Chin RK, Wang J, Wang Y, Schietinger A, Philip M, Schreiber H, Fu YX (2004) Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol 5:141–149CrossRefPubMed

22.

Spiotto MT, Rowley DA, Schreiber H (2004) Bystander elimination of antigen loss variants in established tumors. Nat Med 10:294–298PubMed

23.

Calogero RA, Musiani P, Forni G, Cavallo F (2004) Towards a long-lasting immune prevention of HER2 mammary carcinomas: directions from transgenic mice. Cell Cycle 3:1–4

24.

Quaglino E, Rolla S, Iezzi M, Spadaro M, Musiani P, De Giovanni C, Lollini PL, Lanzardo S, Forni G, Sanges R, Crispi S, De Luca P, Calogero R, Cavallo F (2004) Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions. J Clin Invest 113:709–717CrossRefPubMed

25.

Quaglino E, Iezzi M, Mastini C, Amici A, Pericle F, Di Carlo E, Pupa SM, De Giovanni C, Spadaro M, Curcio C, Lollini PL, Musiani P, Forni G, Cavallo F (2004) Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. Cancer Res 64:2858–2864PubMed

26.

Spadaro M, Lanzardo S, Curcio C, Forni G, Cavallo F (2004) Immunological inhibition of carcinogenesis. Cancer Immunol Immunother 53:204–216CrossRefPubMed

27.

Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP, Forni G (1998) Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J Exp Med 188:589–596CrossRefPubMed

28.

Soares MM, Mehta V, Finn OJ (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555–6563PubMed

29.

Iinuma T, Homma S, Noda T, Kufe D, Ohno T, Toda G (2004) Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J Clin Invest 113:1307–1317CrossRefPubMed

30.

Van Dyke T, Jacks T (2002) Cancer modeling in the modern era: progress and challenges. Cell 108:135–144CrossRefPubMed

31.

Hingorani SR, Petricoin EF, Maitra A, Rajapakse V, King C, Jacobetz MA, Ross S, Conrads TP, Veenstra TD, Hitt BA, Kawaguchi Y, Johann D, Liotta LA, Crawford HC, Putt ME, Jacks T, Wright CV, Hruban RH, Lowy AM, Tuveson DA (2003) Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4:437–450CrossRefPubMed

32.

Rangarajan A, Weinberg RA (2003) Opinion: comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer 3:952–959CrossRefPubMed

33.

Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–2738PubMed

34.

Gilboa E (1999) How tumors escape immune destruction and what we can do about it. Cancer Immunol Immunother 48:382–385CrossRefPubMed

35.

Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S (2000) Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 74:181–273PubMed

36.

Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, Carbone DP (1998) Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92:4150–4166PubMed

37.

Steinman RM, Hawiger D, Liu K, Bonifaz L, Bonnyay D, Mahnke K, Iyoda T, Ravetch J, Dhodapkar M, Inaba K, Nussenzweig M (2003) Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 987:15–25PubMed

38.

Delon J, Stoll S, Germain RN (2002) Imaging of T-cell interactions with antigen presenting cells in culture and in intact lymphoid tissue. Immunol Rev 189:51–63CrossRefPubMed

39.

O’Shaughnessy JA, Kelloff GJ, Gordon GB, Dannenberg AJ, Hong WK, Fabian CJ, Sigman CC, Bertagnolli MM, Stratton SP, Lam S, Nelson WG, Meyskens FL, Alberts DS, Follen M, Rustgi AK, Papadimitrakopoulou V, Scardino PT, Gazdar AF, Wattenberg LW, Sporn MB, Sakr WA, Lippman SM, Von Hoff DD (2002) Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 8:314–346PubMed

40.

Blattman JN, Greenberg PD (2004) Cancer immunotherapy: a treatment for the masses. Science 305:200–205

41.

Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, Zhu L, Kronenberg M, Miller PW, Portanova J, Lee JC, Dubinett SM (2000) Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361–370PubMed

42.

Radisky D, Hagios C, Bissell MJ (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11:87–95

43.

Steinman RM, Dhodapkar M (2001) Active immunization against cancer with dendritic cells: the near future. Int J Cancer 94:459–473CrossRefPubMed

44.

Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R, Fay J (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 61:6451–6458PubMed

45.

Heath WR, Carbone FR (2001) Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 19:47–64CrossRefPubMed

46.

Ferlazzo G, Munz C (2004) NK cell compartments and their activation by dendritic cells. J Immunol 172:1333–1339PubMed

47.

Fujii SI, Shimuzu K, Kronenberg M, Steinman RM (2002) Prolonged interferon-g producing NKT responses induced with a-galactosyl ceramide loaded dendritic cells. Nat Immunol 3:867–874CrossRefPubMed

48.

Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, Mackall CL, Schlom J, Topalian SL, Berzofsky JA (2001) Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 19:1848–1854PubMed

49.

Gjertsen BT, Bruserud O (2004) How should clinical data be included in experimental studies of cancer immunology? Cancer Immunol Immunother 53:677–680CrossRefPubMed

Title: Harnessing host immune responses to preneoplasia: promise and challenges
Author: Madhav V. Dhodapkar
Publication date: 01-05-2005
Publisher: Springer-Verlag
Published in: Cancer Immunology, Immunotherapy / Issue 5/2005
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-004-0607-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2005

Immunotherapy for superficial bladder cancer

In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment

Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-β

Tumor sensitivity to IFN-γ is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors

Induction of specific human primary immune responses to a Semliki Forest virus–based tumor vaccine in a Trimera mouse model

Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer